What does Palisade Bio, Inc. do?
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat…
What is Palisade Bio, Inc.'s P/E and P/B ratio?
Palisade Bio, Inc. has a P/E ratio of 2.2 and a P/B ratio of 1.93.
What is Palisade Bio, Inc.'s debt-to-equity ratio?
Palisade Bio, Inc. has a debt-to-equity ratio of 0.00.
How much does Palisade Bio, Inc. owe compared with what it owns?
Palisade Bio, Inc. owes $0.04 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Palisade Bio, Inc.'s Positivity rank?
Palisade Bio, Inc. is ranked #1,450 of 6,774 companies globally and #324 of 4,000 in United States on PositoAI, with a Positivity Score of 22,737.
Does Palisade Bio, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Palisade Bio, Inc. has no active red flags. It has 1 yellow flag (PosiYellow stress signals, 1/10 points): Pledge-related SEC filings found.
Where can I read the latest news about Palisade Bio, Inc.?
Recent headlines about Palisade Bio, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Palisade Bio, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Palisade Bio, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.